NCT04917861: A reported trial by ModernaTX, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04917861 |
|---|---|
| Title | A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose Confirmation Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Adults Aged 18 Through 65 Years and Living in Endemic and Non-Endemic Flavivirus Areas |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 7, 2021 |
| Completion date | July 26, 2024 |
| Required reporting date | July 26, 2025, midnight |
| Actual reporting date | July 25, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |